MedTrace Logo

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

NCT07286266 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2026-05-27

No results posted yet for this study

Summary

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

Mocertatug rezetecan

Mocertatug rezetecan will be administered

DRUG

Paclitaxel

Paclitaxel will be administered

DRUG

Pegylated liposomal doxorubicin (PLD)

PLD will be administered

DRUG

Topotecan

Topotecan will be administered

DRUG

Gemcitabine

Gemcitabine will be administered

DRUG

Pembrolizumab

Pembrolizumab will be administered

DRUG

Bevacizumab

Bevacizumab will be administered

Sponsors & Collaborators

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • GOG Foundation

    collaborator NETWORK

  • Asia-Pacific Gynecologic Oncology Trials Group

    collaborator OTHER

  • GlaxoSmithKline

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-24
Primary Completion
2030-08-21
Completion
2030-08-21
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07286266 on ClinicalTrials.gov